Constipation Treatment Market to reach US$ 22.93 Bn in 2025; Specialty constipation drugs such as GC-C agonists to witness exponential growth

According to the report, global constipation treatment market was valued at US$ 12.58 Bn in 2016 and is projected to expand at a CAGR of 7.1% from 2017 to 2025 to reach US$ 22.93 Bn by 2025. Irregular frequency of bowel movement with hard stool and strain in passing is termed as constipation. According to Rome IV and other regional guidelines constipation is characterized by low frequency of bowel movement with less than twice a week and strain associated with passing hard stool. Constipation affects all individuals in their lifetime which may be occasional lasting for short period of time or chronic which lasts for longer period and is recurring. Constipation may be functional i.e. chronic idiopathic constipation or associated with other conditions such as irritable bowel syndrome and opioid consumption. Therapeutic drugs used to relief constipation vary as per the type of constipation.

Read Report - https://www.transparencymarketresearch.com/constipation-treatment-market.html

There is high prevalence of chronic constipation as well irritable bowel syndrome with constipation (IBS-C). A paper published in Journal of Neurogastroenterology and Motility in 2010 stated that prevalence of IBS in Asia was 6.5% to 10.1%, of which constipation affected patients were 12% to 77%. Moreover the prevalence of these diseases is on rise in school going children due to changing dietary habits. According to a study conducted by Asociación Mexicana de Gastroenterología, prevalence of functional constipation in school children in Mexico was 12.6% in 2016. According to another study conducted in countries in Asia, the prevalence of constipation among children in Taiwan was 33% in 2016, while it was 12% and 28% in Hong Kong and South Korea, respectively, between 2008 and 2012. Many of the key industry players are investing on development of novel specialty constipation medicines such as linaclotide, lubiprostone, etc. which is estimated to drive the expansion of constipation treatment market. However over reliance on generic and OTC laxatives and scarcity in availability of specialty medicines is anticipated to hamper the growth of market.

Inquire for a Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Based on the therapeutic option, global constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting Mu opioid receptor antagonists, GC-C agonists and 5-HT4 receptor agonists. The laxatives segment is further classified into bulk forming agents, osmotic laxatives, stimulant laxatives, and others. According to a study conducted in 2010 and funded by a key industry player around 50% to 60% of the constipation patients were on laxatives in Latin America and Asia Pacific region. Moreover low cost and wide availability of laxatives has led to their high market share in global constipation treatment market. This segment is likely to expand at CAGR of 7.0% from 2017 to 2025 and hold dominant share in global market. However generic availability of laxatives by local and regional players and growing concern of laxative induced constipation is anticipated to hamper growth of this segment. Better efficiency and wide indications of GC-C agonist drugs is projected to contribute for exponential growth of this segment at CAGR of 8.7% from 2017 to 2025. Based on disease type, global market is segmented into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid induced constipation (OIC). Increasing consumption of opioids for cancerous and non-cancerous pain relief is prone to increase prevalence of OIC. This segment is likely to have growth at CAGR of 7.5% from 2017 to 2025.

Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16442

By distribution channel, the global constipation treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. High preference for self-medication and wide availability of OTC laxatives has contributed for large share on retail pharmacies in global constipation treatment market. This segment is estimated to grow at CAGR of 7.1% from 2017 to 2025.

Geographically the global constipation treatment market is segmented in to North America, Europe and Rest of the World. North America region dominated the global market and is projected to expand at CAGR of 6.9 % over forecast period from 2017 to 2025. High healthcare expenditure, high prevalence of chronic constipation and availability of specialty drugs is projected to contribute for dominating share of North America in global constipation treatment market. Asia Pacific market is estimated to have exponential growth at CAGR of 8.5% during the forecast period owing to high prevalence of IBS-C and increasing healthcare expenditure in emerging markets such as India, China and South-East Asia.

Major companies competing in the constipation treatment market, and profiled in the report include Ironwood Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Limited, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, AstraZeneca, Valeant Pharmaceuticals International, Inc., Cosmo Pharmaceuticals NV, Sanofi, Daewoong Pharmaceuticals Co. Ltd., Bayer AG, Prestige Brands Holdings, Inc., Janssen Pharmaceutical Company, Shionogi & Co., Ltd., Albireo Pharma, Inc., and Renexxion, LLC.

Purchase this Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=16442<ype=S

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.